Clinical trials: Ejection Fraction
Heart Failure With Preserved Ejection Fraction, Beta Blocker
Carvedilol in HF With Preserved EF
Beta-blockers improve clinical outcomes in heart failure and reduced ejection fraction (HFrEF); but not in those with preserved EF.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Beta Blocker, Myocardial Strain
- Trial name
- NCT05553314
- Testing
- Carvedilol
- Where
- 2 sites in South Korea
- Volunteers
- 63 people
- Sponsor
- Seoul National University Bundang Hospital
Heart Failure With Preserved Ejection Fraction
Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction
The goal of this double-blind randomized, placebo-controlled cross-over trial is to evaluate the effectiveness of GerenylGeranylAcetone (GGA) in patients with Heart Failure with a preserved ejection fraction.
- Trial name
- GLADIATOR (NCT05672134)
- Testing
- Iohexol measurement, Geranylgeranylacetone (GGA), Echocardiography
- Where
- Netherlands
- Volunteers
- 43 people
- Sponsor
- Amsterdam UMC, location VUmc
Heart Failure With Preserved Ejection Fraction, Prognathism
Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Factors influencing the prognosis of patients with heart failure with preserved ejection fraction (HFpEF) have been extensively studied.
- Trial name
- NCT06379152
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Chongqing Medical University
Congestive Heart Failure, Heart Failure, Left-Sided
Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial
The enormous and rapidly growing burden of Heart Failure with Preserved Ejection Fraction (HFpEF) has led to a need to understand the pathogenesis and treatment options for this morbid disease.
- Conditions
- Congestive Heart Failure, Heart Failure, Left-Sided, Left-Sided Heart Failure
- Trial name
- BEAT HFpEF (NCT02885636)
- Testing
- Albuterol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Heart Failure, Cardiogenic Shock
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
The study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.
- Conditions
- Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
- Trial name
- INTeGRATE (NCT06965504)
- Testing
- Impella 5.5 SmartAssist
- Where
- 17 sites in United States
- Volunteers
- 250 people
- Sponsor
- Abiomed Inc.
Diastolic Heart Failure
CMR Exercise Stress Testing in HFpEF
Patients of the University Hospital Göttingen with echocardiographic signs for diastolic heart failure and indication for right heart catheterisation will undergo additional diagnostic testing with CMR including exercise stress…
- Trial name
- HFpEF-Stress (NCT03260621)
- Testing
- stress CMR
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- University of Göttingen
Heart Failure With Preserved Ejection Fraction
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
- Trial name
- NCT07083011
- Testing
- 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Chronic Heart Failure With Reduced Ejection Fraction
A Prospective, Single-center, Randomized Controlled Clinical Study Evaluating the Efficacy and Safety of Hyperbaric Oxygen Therapy as an Adjunctive Treatment for Chronic Heart Failure
This study aims to investigate whether adjunctive hyperbaric oxygen therapy, compared to guideline-directed medical therapy with the "New Four Pillars" (ARNI/ACEI/ARB + β-blocker + MRA + SGLT2 inhibitor) alone, improves cardiac…
- Trial name
- NCT07311109
- Testing
- hyperbaric oxygen therapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fujian Medical University
Heart Failure With Preserved Ejection Fraction, Hypertension, Renal
Renal Denervation to Treat Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction has a high mortality, which is contrasted by a total absence of therapy options besides symptomatic diuretic treatment.
- Trial name
- UNLOAD-HFpEF (NCT05030987)
- Testing
- Renal Denervation
- Where
- 5 sites in Germany
- Volunteers
- 68 people
- Sponsor
- University of Leipzig
Heart Failure
Efficacy and Safety of Xinyue Capsule in the Treatment of Heart Failure With Preserved Ejection Fraction
The purpose of this study is to evaluate the effect of Xinyue Capsule in the improvement cardiac function and reduction the level of heart failure biomarker NT-proBNP in patients suffering from HF with an ejection fraction…
- Trial name
- NCT06946095
- Testing
- Chinese patent medicine
- Volunteers
- 246 people
- Sponsor
- Beijing Anzhen Hospital
Heart, Heart Failure With Preserved Ejection Fraction (HFPEF)
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
- Trial name
- NCT07219511
- Testing
- VS-041
- Where
- 21 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vasa Therapeutics
Drug Effect
The Effects of Sacubitril/Valsartan on the Heart Functions
Background: Sacubitril/valsartan, has been found to be more beneficial than enalapril for reducing the incidences of sudden cardiac death, death from worsening heart failure (HF), and hospitalization.
- Trial name
- NCT03830814
- Testing
- Echocardiography
- Volunteers
- 100 people
- Sponsor
- The Young Investigator Group of Cardiovascular Research
Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease
In patients with ESRD, up to 20% of patients suffer from HFrEF, leading to significant CV morbidity and mortality. Several drug classes that provide survival benefits for patients with HFrEF, including SGLT2i, lack data regarding…
- Trial name
- EMPA-RRED (NCT06249932)
- Testing
- Empagliflozin 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 95 people
- Sponsor
- National Taiwan University Hospital
Heart Failure, Diastolic, Weight Loss
Weight Loss as Therapy for Heart Failure With Preserved Ejection Fraction
The purpose of this study is to examine the efficacy of an intensive, supervised, lifestyle modification program on symptoms and signs of heart failure as well as laboratory and echocardiographic measures of cardiac structure and…
- Trial name
- WTLSSCHF (NCT02911337)
- Testing
- lifestyle modification
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Heart Failure, Diastolic, Hypertension
Renal Denervation in Patients With Heart Failure With Normal LV Ejection Fraction
It is a randomized prospective controlled study of transcatheter renal denervation in patients with Heart Failure With Normal LV Ejection Fraction.
- Trial name
- NCT02115230
- Testing
- Renal denervation + medical therapy
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- InCor Heart Institute
Heart Failure With Preserved Ejection Fraction (HFPEF)
This Will be a Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection Fraction
The SPECTRA-HFpEF Study is a randomized, double-blind, Phase 2 clinical study designed to evaluate and compare the biological effects of vicadrostat in combination with empagliflozin, empagliflozin alone, and spironolactone in…
- Trial name
- SPECTRA-HFpEF (NCT07857772)
- Testing
- empa plus vica, Comparator: empa 10 plus spironolactone
- Volunteers
- 200 people
- Sponsor
- Baim Institute for Clinical Research
ST Elevation Myocardial Infarction
The Effect of Low-Level Tragus Stimulation on Echocardiographic Parameters in Patients With ST-Segment Elevation Myocardial Infarction - A Single-Centre Randomized Control Trial
The goal of this clinical trial is to learn the effect of low level tragus stimulation (LLTS) on echocardiographic parameter in patient with ST-segment Elevation Myocardial Infarction (STEMI) who undergo primart percutaneous…
- Trial name
- ELITE-STEMI (NCT07058857)
- Testing
- Parasym Neuromodulation Device (Treatment Group)
- Where
- Indonesia
- Volunteers
- 100 people
- Sponsor
- Universitas Diponegoro
COPD (Chronic Obstructive Pulmonary Disease), Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)
Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course and Prognosis
Study aim is comparison of heart failire with preserved ejection fraction (HFpEF) detection rate in patients with Сhronic Obstructive Pulmonary Disease (COPD) and the clinical course and prognosis in patients with COPD depending…
- Trial name
- HIPSTER (NCT07375433)
- Testing
- Echocardiography, Spirometry, Body plethysmography
- Where
- 2 sites in Russia
- Volunteers
- 200 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Heart Failure, Beta-blocker
N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure
In this study we seek to understand whether N-of-1 trials using a crossover withdrawal/reversal design with 1-5 three-week periods can be used to identify the highest tolerated beta-blocker dose for patients with Heart Failure…
- Conditions
- Heart Failure, Beta-blocker, Older Adults
- Trial name
- NCT07489352
- Testing
- N-of-1 trials, Enhanced usual care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure With Preserved Ejection Fraction
Transthyretin Cardiac Amyloidosis in HFpEF
To estimate the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among Heart Failure with Preserved Ejection Fraction (HFpEF) patients with increased LV wall thickness in Southeast Minnesota using 99mTc-PYP single-photon…
- Trial name
- NCT03414632
- Testing
- 99mTc-PYP
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.